Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Dermatologic 2CNS 2Head & Neck 1

Conditions

Glioblastoma 45Brain Neoplasms 35Glioma 27Astrocytoma 22Gliosarcoma 15Central Nervous System Neoplasms 15Oligodendroglioma 13Neoplasm Metastasis 7Neuroblastoma 5Neoplasms 5Meningioma 4Craniopharyngioma 4Pinealoma 3Medulloblastoma 3Glioma, Subependymal 3Recurrence 2Ependymoma 2Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neuroectodermal Tumors, Primitive 1Meningiomas of the Middle Cranial Fossa 1Hemangioma, Cavernous, Central Nervous System 1Esthesioneuroblastoma, Olfactory 1Dyschromatosis symmetrica hereditaria 1 1Choroid Plexus Neoplasms 1

Interventions

Temozolomide 23Bevacizumab 18Cyclophosphamide 9Carboplatin 7Lomustine 6Irinotecan 63-Iodobenzylguanidine 6Topotecan 5Radiotherapy 5Filgrastim 5Radiosurgery 4Nivolumab 4Everolimus 4Etoposide 4Busulfan 4sonidegib 3pembrolizumab 3olaparib 3fludarabine phosphate 3fludarabine 3antineoplaston AS 2-1 3antineoplaston A10 3Vincristine 3Thiotepa 3Sirolimus 3Melphalan 3IL13-PE38 3Drug Therapy 3Antilymphocyte Serum 3verubulin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Surgical Procedures, Operative × CNS × Clear all
NCT00024570 2014-11-14

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

INSYS Therapeutics Inc

Phase 1/2 Completed
60 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

NCT00024557 2011-06-06

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

INSYS Therapeutics Inc

Phase 1 Completed
40 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡